SCM
ADMA icon

Stonepine Capital Management’s ADMA Biologics ADMA Stock Holding History

Stonepine Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4M Buy
+1,150,000
New +$18.1M 4.15% 5

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Stonepine Capital Management's ADMA Position: Q1 2026 in Review

Stonepine Capital Management held its ADMA Biologics (ADMA) position steady in Q1 2026 at 740,000 shares worth $6.67M. The position accounts for 2.67% of the portfolio, ranked #7.

Stonepine Capital Management first reported a position in ADMA in Q4 2017 and has held it in 20 quarters since. The position peaked at $41.7M in Q4 2023. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Stonepine Capital Management held 740,000 shares of ADMA Biologics worth $6.67M as of Q1 2026.
  • Stonepine Capital Management left its ADMA Biologics share count unchanged in Q1 2026.
  • ADMA Biologics made up 2.67% of Stonepine Capital Management's portfolio in Q1 2026, its #7 holding.
  • Stonepine Capital Management first reported a position in ADMA Biologics in Q4 2017 and has held it in 20 quarters since.
  • Stonepine Capital Management's ADMA Biologics position peaked at $41.7M in Q4 2023.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.